OTC · Consumer discretionary

Acro Biomedical CO., Ltd. (ACBM)

Acro Biomedical CO., Ltd. brought in $0 of revenue over the twelve months to June 30, 2026. It posted a net loss of $140.4K. At June 30, 2026 it held $3.6K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Watch ACBM in 60 seconds

Price

$0.03

0.00% on the day · September 25, 2026

52-week range $0.00 to $0.10

Market cap

$1.6M

Revenue (last 12 months)

What Acro Biomedical CO., Ltd. does

Acro Biomedical CO., Ltd. is registered with the SEC under industry code SIC 7900 (Services-Amusement & Recreation Services). Its shares trade on OTC under the ticker ACBM.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$0	-$154K	-$101.1K	$0.00	n/a
2024	$0	-$38K	-$42.3K	$0.00	n/a
2023	$0	-$8.8M	-$8.8M	-$0.15	n/a
2022	$658.5K	-$15.9M	-$15.9M	-$0.26	n/a
2021	$1.2M	-$7.7M	-$7.7M	-$0.14	n/a
2020	$688K	-$130.5K	-$117.5K	$0.00	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 9, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 10, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Acro Biomedical CO., Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 2, 2026
Executive or director change 8-K
August 14, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS $0.00 versus $0.00.
May 5, 2026
Quarterly report 10-Q · period to March 31, 2026Diluted EPS $0.00 versus $0.00.
February 11, 2026
Annual report 10-K · period to December 31, 2025Diluted EPS $0.00 versus $0.00.
January 8, 2026
Auditor change 8-K
November 10, 2025
Quarterly report 10-Q · period to September 30, 2025Diluted EPS $0.00 versus $0.00.
August 14, 2025
Executive or director change 8-K
August 5, 2025
Quarterly report 10-Q · period to June 30, 2025Diluted EPS was $0.00.
July 24, 2025
Quarterly report 10-Q · period to March 31, 2025Diluted EPS was $0.00.
July 24, 2025
Annual report 10-K · period to December 31, 2024Diluted EPS $0.00 versus -$0.15.

Recent insider filings (Forms 3, 4 and 144): 1, the latest on February 26, 2021. Insider transactions on SEC

All filings on SEC EDGAR

Questions about ACBM

What does Acro Biomedical CO., Ltd. do?

Acro Biomedical CO., Ltd. is registered with the SEC under industry code SIC 7900 (Services-Amusement & Recreation Services). Its shares trade on OTC under the ticker ACBM.

Is Acro Biomedical CO., Ltd. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $140.4K.

How much revenue does Acro Biomedical CO., Ltd. make?

Over the twelve months to June 30, 2026 Acro Biomedical CO., Ltd. reported revenue of $0.

When did Acro Biomedical CO., Ltd. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from September 2, 2026.

Similar companies

LYV

Live Nation Entertainment, Inc.

WMG

Warner Music Group Corp.

TKO

TKO Group Holdings, Inc.

FUN

Six Flags Entertainment Corporation

ACEL

Accel Entertainment, Inc.

LUCK

Lucky Strike Entertainment Corp

Compare ACBM with

Compare ACBM with any company

Follow ACBM

Get an email when Acro Biomedical CO., Ltd. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ACBM: get an email when it files

Where the numbers come from

Financial figures are the values Acro Biomedical CO., Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.